Company Information
Industry 制造业
Company Introduction 首药控股(北京)股份有限公司成立于2016年4月19日,专注于具有自主知识产权的创新药的研发和生产,目前已获得国家1类创新药临床批件18个,其中1个新药申报上市、1个新药完成临床Ⅲ期、5个新药进入临床Ⅱ期、10个新药进入临床I期。让我们在“责、权、利”清晰而又扛得住的机制里,把首药控股锻造成为集研发、生产、销售于一体的国际化药企。
Main Business 从事小分子靶向创新药的研发
Legal Representative 李文军
Top Executives
董事长:李文军
董事:王静晗,李庭,许新合
独立董事:刘学,杨国杰,江骥
Top 5 Shareholder
Shareholder name Nature Holding Date
李文军限售股49.05%30/09/2024
北京亦庄国际投资发展有限公司流通A股4.90%30/09/2024
中国农业银行股份有限公司-鹏华医药科技股票型证券投资基金流通A股3.64%30/09/2024
北京双鹭药业股份有限公司流通A股3.54%30/09/2024
张静限售股3.36%30/09/2024
Company Secretary 张英利
Solicitors 北京市竞天公诚律师事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 010-88857906
Fax No 010-88853760
Website www.shouyaoholding.com
Email shouyaoholding@163.com
Company Address
Register: 北京市北京经济技术开发区荣华中路10号1幢A座22层2205
Office: 北京市海淀区闵庄路3号玉泉慧谷15号楼
Listing Date 23/03/2022
Shares Capital
Shares Capital: 148,719,343
Total A Share: 148,719,343
Listed A Share: 55,766,242
Non-tradable A Share: 92,953,101
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -1.250
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 6.865
Market Capitalization(RMB) 1.893B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.